The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 2026-11 · 83 (5) · 819-821
DOI: 10.1002/jpn3.70534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 13.08.2026. Verfasst von Michael P Duggan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Mattel Children's Hospital, University of California, Los Angeles, California, U…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Mattel Children's Hospital, University of California, Los Angeles, California, USA.
ORCID-Profile: Michael P Duggan
Förderung
- None
Zitieren
APA
Duggan, M. P., Katsanos, E. D., & Hamandi, H. (2026). The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition, 83(5), 819-821. https://doi.org/10.1002/jpn3.70534
Vancouver
Duggan MP, Katsanos ED, Hamandi H. The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2026;83(5):819-821. doi:10.1002/jpn3.70534
BibTeX
@article{Duggan2026,
author = {Duggan, Michael P and Katsanos, Evangelos D and Hamandi, Hassan},
title = {The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {83},
number = {5},
pages = {819--821},
doi = {10.1002/jpn3.70534}
}
EUVIMED